DURHAM, NC (USA) and LIEGE (BELGIUM) - OncoMethylome Sciences announced today that it will perform MGMT gene methylation testing for a multi-center clinical trial for patients with brain tumors conducted jointly by the U.S.-based Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). With patient enrollment underway, the trial was designed to determine whether increasing the intensity of temozolomide drug treatment regimen for patients with glioblastoma multiforme tumors improves clinical outcomes over standard-dose temozolomide. This phase III trial brings together a valuable network of international medical centers and universities and is the first such collaborative study between RTOG and EORTC organizations.

The clinical trial builds on a recent EORTC/NCI-C study published in the New England Journal of Medicine (2005; 352: 997-1003) which demonstrated that brain tumor patients with methylated, or silenced, DNA repair enzyme gene MGMT had a more favorable survival response to temozolomide therapy than patients with unmethylated, or expressed, MGMT gene. Consequently, the goal of the current trial is to analyze whether all glioblastoma patients, but especially those with unmethylated MGMT, can benefit from a more intensive temozolomide treatment regimen. To assist in this effort, OncoMethylome Sciences will be providing testing services to determine the methylation status of the MGMT gene in brain tumor patients enrolled in the trial.

"Brain tumors are among the most aggressive and fatal adult tumors," stated Walter J. Curran, Jr, MD, Group Chair of the RTOG. "By joining forces with other international cancer experts, such as the EORTC, and utilizing the promising new OncoMethylome Sciences' test, we hope to contribute to a significant improvement in treatment of brain tumor patients."

"OncoMethylome is very proud to be involved in current efforts to improve brain tumor treat
'"/>

Contact: Harry Schrickx, OncoMethylome Sciences (USA)
Harry.Schrickx@oncomethylome.com
919-281-0980
University of Liege
5-Apr-2006

Page: 1 2
Related medicine news :

1. Rush researchers participate in worldwide AIDS initiative led by Imperial College London
2. UB diabetes researchers participate in international study
3. UVa participates in landmark breast cancer screening trial
4. Women want information, opportunity to participate in decision for first mammogram
5. Quality of care not necessarily better in hospitals that participate in quality improvement program
6. Northwestern Memorial participates in trial to test effectiveness of drug to treat endometriosis
7. Researchers suggest TB screening for all international adoptees
8. Cedars-Sinai researchers present new endocrine findings at 2 international conferences
9. MUHC-led international team identifies gene responsible for blindness in infants and children
10. WFU to host international conference of physicists
11. Pioneering UK skin researchers achieve international quality standard